Typically, 2/3 of NAFLD-HCC tumors show OGT overexpression, while 1/3 of no change in OGT expression is seen, suggesting that OGT expression is associated with gene polymorphism related to the occurrence and progression of NAFLD and NASH, such as PNOLA3 p.I148M, TM6SF2 p.E167K, and MBOAT7 rs641738 [95,96]. The gene discussed is TM6SF2; the disease is metabolic dysfunction-associated steatotic liver disease.